Top Cited Articles

Acceptance rate

27%

Impact Factor (JCR):

12.469

IF rank (Oncology)

25/245

IF rank (Immunology)

18/161

Citescore

14.3

2021 total content views

872,390

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, Lorenzo; Vitale, Ilio; Warren, Sarah; et al
10.1136/jitc-2019-000337

TIGIT in cancer immunotherapy
Chauvin, Joe-Marc; Zarour, Hassane M.
10.1136/jitc-2020-000957

Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, Nandini; Sabatos-Peyton, Catherine; Anderson, Ana Carrizosa
10.1136/jitc-2020-000911

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Brahmer, Julie R.; Abu-Sbeih, Hamzah; Ascierto, Paolo Antonio; et al
10.1136/jitc-2021-002435

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Merino, Diana M.; Mcshane, Lisa M.; Fabrizio, David; et al
10.1136/jitc-2019-000147

Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer
Sun, Jie; Zhang, Zicheng; Bao, Siqi; et al
10.1136/jitc-2019-000110

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Rischin, Danny; Migden, Michael R.; Lim, Annette M.; et al
10.1136/jitc-2020-000775

Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-beta RII agent: status of preclinical and clinical advances
Lind, Hanne; Gameiro, Sofia R.; Jochems, Caroline; et al
10.1136/jitc-2019-000433

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
D’Angelo, Sandra P.; Bhatia, Shailender; Brohl, Andrew S.; et al
10.1136/jitc-2020-000674

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Maus, Marcela, V; Alexander, Sara; Bishop, Michael R.; et al
10.1136/jitc-2020-001511

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Efimova, Iuliia; Catanzaro, Elena; Van der Meeren, Louis; et al
10.1136/jitc-2020-001369

LAG-3: from molecular functions to clinical applications
Maruhashi, Takumi; Sugiura, Daisuke; Okazaki, Il-mi; et al
10.1136/jitc-2020-001014

Clinical landscape of oncolytic virus research in 2020
Macedo, Nicholas; Miller, David M.; Haq, Rizwan; et al
10.1136/jitc-2020-001486

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Ferrucci, Pier Francesco; Di Giacomo, Anna Maria; Del Vecchio, Michele; et al
10.1136/jitc-2020-001806

IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
Zhang, Wenjie; Liu, Yang; Yan, Zhongyi; et al
10.1136/jitc-2019-000285

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Guidon, Amanda C.; Burton, Leeann B.; Chwalisz, Bart K.; et al
10.1136/jitc-2021-002890

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Taube, Janis M.; Akturk, Guray; Angelo, Michael; et al
10.1136/jitc-2019-000155

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
Cortellini, Alessio; Tucci, Marco; Adamo, Vincenzo; et al
10.1136/jitc-2020-001361

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
Welsh, James; Menon, Hari; Chen, Dawei; et al
10.1136/jitc-2020-001001

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
He, Bingxi; Dong, Di; She, Yunlang; Zhou, Caicun; et al
10.1136/jitc-2020-000550